EBITDA Margin % is calculated as EBITDA divided by its Revenue. Perrigo Co's EBITDA for the
three
months ended in Mar. 2026 was MXN-5,129 Mil. Perrigo Co's Revenue for the
three
months ended in Mar. 2026 was MXN17,477 Mil. Therefore, Perrigo Co's EBITDA margin for the quarter that ended in Mar. 2026 was -29.34%.
Perrigo Co (MEX:PRGON) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Perrigo Co EBITDA Margin % Related Terms
Perrigo Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Perrigo Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRGON vs AMLX, HROW, ANIP: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Perrigo Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perrigo Co (MEX:PRGON) has a EBITDA Margin % of -29.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Perrigo Co and its competitors. According to the industry distribution chart, Perrigo Co ranks #823 out of 955 companies in the Drug Manufacturers industry, placing it in the top 86.2%.
Is Perrigo Co's EBITDA Margin % too high?
Perrigo Co's current EBITDA Margin % is -29.34%. Based on the distribution chart, Perrigo Co ranks #823 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Perrigo Co has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's EBITDA Margin % compare to AMLX and HROW?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #823 out of 955 companies for EBITDA Margin %. This places Perrigo Co in the lower half of its industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Perrigo Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perrigo Co's current EBITDA Margin % is -29.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Perrigo Co (MEX:PRGON) has a current EBITDA Margin % of -29.34%. The stock's GF Value™ is MXN1,468.70, compared to a current price of MXN557.52 — trading 62% below its estimated fair value. The current EBITDA Margin % is -29.34%. Perrigo Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Perrigo Co (MEX:PRGON), the current EBITDA Margin % is -29.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (MEX:PRGON) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of MXN557.52 is trading 62% below its estimated GF Value™ of MXN1,468.70.
Key valuation signals for MEX:PRGON:
EBITDA Margin %: -29.34%
GF Value™: MXN1,468.70 vs. price of MXN557.52 (62% below fair value)
No single metric tells the full story. See the MEX:PRGON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
44GF Score
Get the complete analysis for MEX:PRGON
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRGON has been successfully added to your 
